98%
921
2 minutes
20
Respiratory syncytial virus (RSV) is the leading cause of hospitalisation for respiratory infection in young children. RSV disease severity is known to be age-dependent and highest in young infants, but other correlates of severity, particularly the presence of additional respiratory pathogens, are less well understood. In this study, nasopharyngeal swabs were collected from two cohorts of RSV-positive infants <12 months in Spain, the UK, and the Netherlands during 2017-20. We show, using targeted metagenomic sequencing of >100 pathogens, including all common respiratory viruses and bacteria, from samples collected from 433 infants, that burden of additional viruses is common (111/433, 26%) but only modestly correlates with RSV disease severity. In contrast, there is strong evidence in both cohorts and across age groups that presence of Haemophilus bacteria (194/433, 45%) is associated with higher severity, including much higher rates of hospitalisation (odds ratio 4.25, 95% CI 2.03-9.31). There is no evidence for association between higher severity and other detected bacteria, and no difference in severity between RSV genotypes. Our findings reveal the genomic diversity of additional pathogens during RSV infection in infants, and provide an evidence base for future causal investigations of the impact of co-infection on RSV disease severity.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10944482 | PMC |
http://dx.doi.org/10.1038/s41467-024-46648-3 | DOI Listing |
J Microbiol Immunol Infect
September 2025
Department of Pediatrics, MacKay Children's Hospital and MacKay Memorial Hospital, Taipei, Taiwan.
Background: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants and young children. The COVID-19 pandemic significantly disrupted global RSV epidemiology. This study aimed to investigate the impact of the pandemic on RSV epidemiology in northern Taiwan from 2018 to 2023.
View Article and Find Full Text PDFInfect Dis Ther
September 2025
GSK Vaccines, Avenue Fleming 20, 1300, Wavre, Belgium.
Introduction: Limited data are available on the epidemiology and clinical burden of respiratory syncytial virus (RSV) among adults with underlying medical or immunocompromising conditions ("high-risk adults") and ≥ 50-year-old adults in developing countries.
Methods: To better understand the impact of RSV in these populations, a systematic literature review of articles published from the year 2000 onward reporting RSV data among high-risk 18-59-year-old adults and ≥ 50-year-old adults in low, lower-middle, upper-middle, and selected high-income countries was undertaken. Searches were run on Medical Literature Analysis and Retrieval System Online (MEDLINE) and Excerpta Medica DataBASE (EMBASE), and were supplemented by additional searches (e.
Can Commun Dis Rep
August 2025
Département de médecine sociale et préventive, Faculté de médecine, Université Laval, Québec, QC.
Background: Respiratory syncytial virus (RSV) is a common respiratory virus. In addition to infants, older adults are at higher risk of severe outcomes due to RSV, particularly advanced-age older adults and those with chronic medical conditions. The authorization of three vaccines, one for adults 50 years of age and older (Arexvy) and two for adults 60 years of age and older (Abrysvo and mRESVIA), offers the opportunity to protect older Canadians from RSV disease.
View Article and Find Full Text PDFClin Exp Pediatr
September 2025
Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants and young children. In April 2024, the Korea Ministry of Food and Drug Safety approved nirsevimab (Beyfortus), a long-acting monoclonal antibody, as a passive immunization to prevent RSV-associated LRTI among infants and young children. Nirsevimab was launched in Korea in February 2025.
View Article and Find Full Text PDFAm J Trop Med Hyg
September 2025
Department of Tropical Medicine and Infectious Diseases, Tulane University Celia, Scott Weatherhead School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections in children under 5 years of age, resulting in significant morbidity and mortality worldwide. The aim of the current study is to investigate the prevalence and clinical features of RSV disease in hospitalized infants in Sierra Leone. A prospective study was conducted on children under 2 years of age who were hospitalized at Kenema Government Hospital between October 1, 2020, and January 31, 2023.
View Article and Find Full Text PDF